Gail V Matthews
Overview
Explore the profile of Gail V Matthews including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
159
Citations
2621
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Martinello M, Carson J, Post J, Finlayson R, Baker D, Read P, et al.
Open Forum Infect Dis
. 2024 Dec;
11(12):ofae665.
PMID: 39691290
Background: Approximately 10% of people with HIV in Australia had active hepatitis C virus (HCV) infection prior to availability of government-subsidized direct-acting antiviral (DAA) therapy in 2016. This analysis evaluated...
2.
Harney B, Sacks-Davis R, Van Santen D, Stewart A, Matthews G, Carson J, et al.
Liver Int
. 2024 Dec;
45(1):1-13.
PMID: 39656170
Background: Historically, hepatitis C virus (HCV) was difficult to treat among people with HIV. However, treatment with direct-acting antivirals (DAAs) results in 90%-95% of people being cured. There is a...
3.
Han W, Sazzad H, Bloch M, Baker D, Roth N, Bowden-Reid E, et al.
Cell Rep Med
. 2024 Dec;
5(12):101835.
PMID: 39626674
While HIV infection and clonal hematopoiesis (CH) have been linked with inflammatory dysregulation and an increased risk of aging-related comorbidities, their relationship with clinical geriatric syndromes has not been well...
4.
Papot E, Tovar-Sanchez T, Woods J, Thaurignac G, Eriobu N, Borok M, et al.
AIDS
. 2024 Nov;
39(4):448-456.
PMID: 39576151
Objective: Data on the impact of coronavirus disease 2019 (COVID-19) in people with HIV (PWH) are lacking in resource-constrained settings. We utilized existing randomized clinical trials (RCTs) on antiretroviral therapies...
5.
Reilly C, Mylonakis E, Dewar R, Young B, Nordwall J, Bhagani S, et al.
J Infect Dis
. 2024 Sep;
PMID: 39269490
Background: Biomarker guided therapy could improve management of COVID-19 inpatients. Although some results indicate that antibody tests are prognostic, little is known about patient management using point-of-care (POC) antibody tests....
6.
Martinello M, Matthews G
JAMA Netw Open
. 2024 Aug;
7(8):e2430290.
PMID: 39186277
No abstract available.
7.
Nyein P, Petoumenos K, Dharan N, Hanson J, Matthews G
Clin Infect Dis
. 2024 Jun;
PMID: 38938177
No abstract available.
8.
Nyein P, Petoumenos K, Borok M, Eriobu N, Kumarasamy N, Avihingsanon A, et al.
Clin Infect Dis
. 2024 May;
80(1):160-163.
PMID: 38721980
In this randomized controlled study, individuals taking dolutegravir+darunavir/ritonavir had greater increases in systolic and diastolic blood pressure than those taking 2 nucleoside reverse-transcriptase inhibitors+darunavir/ritonavir at week-48. The difference remained significant...
9.
Phetsouphanh C, Jacka B, Ballouz S, Jackson K, Wilson D, Manandhar B, et al.
Nat Commun
. 2024 Apr;
15(1):3315.
PMID: 38632311
This study investigates the humoral and cellular immune responses and health-related quality of life measures in individuals with mild to moderate long COVID (LC) compared to age and gender matched...
10.
Harney B, Sacks-Davis R, Agius P, Van Santen D, Traeger M, Wilkinson A, et al.
Open Forum Infect Dis
. 2024 Apr;
11(4):ofae099.
PMID: 38560602
Background: In Australia, the incidence of hepatitis C virus (HCV) has declined among gay and bisexual men (GBM) with human immunodeficiency virus (HIV) since 2015 and is low among GBM...